Analysis of the Molecular Determinants of the Response of Chronic Myelogenous Leukaemia to Tyrosine Kinase Inhibitors

By  

Current Pharmacogenomics, Vol. 5, Iss. 3, 2007-09 ,pp. : 201-213

Bentham Science Publishers

Access to resources Recommend Favorite

New Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia

By  

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 5, 2006-10 ,pp. : 371-379

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia

By Prescott Hillary   Kantarjian Hagop   Cortes Jorge   Ravandi Farhad  

Expert Opinion on Emerging Drugs, Vol. 16, Iss. 3, 2011-09 ,pp. : 407-423

Informa Healthcare

Access to resources Recommend Favorite

Bypass Mechanisms of Resistance to Tyrosine Kinase Inhibition in Chronic Myelogenous Leukaemia

By  

Current Drug Discovery Technologies, Vol. 11, Iss. 2, 2014-06 ,pp. : 145-153

Bentham Science Publishers

Access to resources Recommend Favorite

Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis

By Soverini Simona   Martinelli Giovanni   Rosti Gianantonio   Iacobucci Ilaria   Baccarani Michele  

Pharmacogenomics, Vol. 13, Iss. 11, 2012-08 ,pp. : 1271-1284

Future Medicine

Access to resources Recommend Favorite